摘要
目的分析伏立康唑+伊曲康唑、伏立康唑单独使用在血液恶性肿瘤继发真菌感染患者治疗中的应用效果差异。方法选取2017年6月~2018年6月我院收治的120例血液恶性肿瘤继发真菌感染患者作为研究对象,根据患者入院先后顺序,将其分为观察组和参照组,每组各60例。观察组患者采用伏立康唑+伊曲康唑治疗,参照组患者采用伏立康唑治疗。比较两组患者的治疗效果、不良反应发生情况、治疗前后炎症因子[肿瘤坏死因子α(TNF-α)、白介素-4(IL-4)、白介素-10(IL-10)、白介素-12(IL-12)]含量、临床症状(高热、咳嗽、咳痰、恶心、感染性休克、呼吸衰竭)好转时间。结果观察组患者的治疗总有效率高于参照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。治疗前,两组患者的TNF-α、IL-12、IL-4、IL-10含量比较,差异无统计学意义(P<0.05)。治疗后,两组患者的TNF-α、IL-12含量均低于本组治疗前,IL-4、IL-10含量均高于本组治疗前,差异有统计学意义(P<0.05)。治疗后,观察组患者的TNF-α、IL-12含量均低于参照组,IL-4、IL-10含量均高于参照组,差异有统计学意义(P<0.05)。观察组患者的高热、咳嗽、咳痰、恶心、感染性休克、呼吸衰竭的好转时间均短于对照组,差异有统计学意义(P<0.05)。结论血液恶性肿瘤继发真菌感染患者应用伏立康唑+伊曲康唑治疗,临床效果确切,而且能及早改善患者的临床症状及炎症因子水平,适合临床应用和推广。
Objective To analyze the difference of efficacy of Voriconazole+Itraconazole and Voriconazole alone in the treatment of patients with secondary fungal infections of hematological malignancies. Methods A total of 120 patients with secondary fungal infections of hematological malignancies treated in our hospital from June 2017 to June 2018 were selected as the research objects. According to the sequence of admission, the patients were divided into observation group and reference group, with 60 cases in each group. Patients in the observation group were treated with Voriconazole+Itraconazole, and patients in the reference group were treated with Voriconazole alone. The therapeutic effect, the incidence of adverse reactions, the levels of inflammatory factors(tumor necrosis factor α [TNF-α], interleukin-4 [IL-4], interleukin-10 [IL-10], interleukin-12 [IL-12]) before and after treatment, improvement time of clinical symptoms(fever, cough, sputum, nausea, septic shock, and respiratory failure) were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Before treatment, there were no statistically significant differences in the contents of TNF-α, IL-12, IL-4 and IL-10 between the two groups(P<0.05). After treatment, the levels of TNF-α, IL-12 in both groups were lower than those before treatment, and the levels of IL-4 and IL-10 were higher than those before treatment, with statistical differences(P<0.05). After treatment, the levels of TNF-α and IL-12 in the observation group were lower than those in the control group, and the levels of IL-4 and IL-10 were higher than those in the control group, with statistical differences(P<0.05). The improvement time of fever, cough, sputum, nausea, septic shock, and respiratory failure in the observation group was shorter than that in the control group, and the difference was statistically significant(P<0.05). Conclusion The application of Voriconazole+Itraconazole in the treatment of patients with secondary fungal infections of hematological malignancies has definite clinical effects, and it can improve the clinical symptoms and inflammatory factor levels of patients as soon as possible, which is suitable for clinical application and promotion.
作者
蒋鹏飞
刘佳
JIANG Peng-fei;LIU Jia(Department of Oncology and Hematology,Jingmen Traditional Chinese Medicine Hospital,Hubei Province,Jingmen448000,China;Department of Rehabilitation,Jingmen Traditional Chinese Medicine Hospital,Hubei Province,Jingmen448000,China)
出处
《中国当代医药》
2020年第11期95-98,共4页
China Modern Medicine
关键词
伏立康唑
伊曲康唑
血液恶性肿瘤
真菌感染
治疗效果
Voriconazole
Itraconazole
Hematological malignancies
Fungal infection
Therapeutic effect
